Supporting strategic fundamental research in life sciences through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications.
Alain Chariot (WELBIO – ULiège) and his team demonstrated the key role of ELP3-mediated tRNA modifications in the biology of immune cells.
David Alsteens (WELBIO – UCLouvain) et son équipe démontrent l’interaction entre les acides sialiques à la surface cellulaire et la protéine spike, et développent des molécules qui permettent de bloquer cette interaction in vitro.
Thomas Marichal (WELBIO - ULiège) est le lauréat du prestigieux Prix Baillet Latour Biomedical qui vise à soutenir pendant 5 ans la carrière de jeunes chercheurs/chercheuses prometteurs dans le domaine des sciences biomédicales.
WELBIO supports excellence in strategic basic research in life sciences. This mission is carried out within the framework of the « Fonds de la Recherche Fondamentale Stratégique » (FRS-FNRS).
WELBIO regularly meets with WELBIO Investigators and TTO representatives to discuss scientific advances, identify intellectual property and facilitate the translation of discoveries into biotechnology applications.
The Bridge Fund is a funding instrument intended for WELBIO Investigators and designed to bridge the gap between early-stage intellectual property and the development of a competitive package for the next technology transfer step.
WELBIO has gradually built up valorization opportunities that are taking many forms including projects supported by Biowin and SPW Research, licensing agreements, industry partnerships, and spin-off creation.
